Country-specific Q&A provides an overview of Pharmaceutical Advertising laws and regulations applicable in Russia.

• pdf, 3.18 Mb

Lidings’ managing partner, Head of the pharmaceuticals and healthcare industry practice and partner in bankruptcy and restructuring practice of the Firm Alexander Popelyuk will speak at the annual conference entitled Pharma – 2020: Pricing, Labeling, Intellectual Property and Legal Risks. The event organized by Pravo.ru will take place in Moscow on October 27th, 2020 at the Marriott Royal Aurora hotel.

Eurasian Virtual Pharmaceutical Summit will take place on October 14-21, 2020. Lidings’ managing partner Andrey Zelenin and partner of the Firm’s Intellectual Property practice Boris Malakhov will speak at the event.

4 September 2020 the Russian Ministry of Justice registered the Order No. 5527 of Roszdravnadzor dd. 29 June 2020, approving criteria for evaluating the information, publication of which may result in a website inclusion in the register of prohibited websites and its blocking. The Federal Service for Surveillance in Healthcare (Roszdravnadzor) renders such a decision.

July 10th 2020, Julia Kuzmenko, Associate in Lidings’ Corporate and M&A practice, will take part in a 3rd Annual Conference on Compliance Enforcement in the Pharmaceutical Industry. The event is organized by MBS Agency and this year will take place in online format.

Specification of the information about the license is not required directly in the advertising of medical activities that are subject to licensing. Verification of the presence of relevant documents is carried out at the request of the advertising distributor in accordance with article 13 of the Law on advertising. The advertiser, in turn, shall provide reports, including information about the availability of a license, mandatory certification and state registration.

The new review of the most notable antitrust disputes in Life Sciences in Russia and CIS.

• pdf, 946.35 kb

On October 18, 2018 new wording of the Rules of state registration and re-registration of maximum sale prices established by drug manufacturers for those drugs, that are included in the vital and essential drugs list (“the Rules” and “the Drugs” correspondingly) has been enacted with the amendments introduced by the Russian Government Decree of 08.10.2018 No. 1207 “On amendments to the Russian Government Decree of October, 29 2010 No. 865 and of September, 15 2015 No. 979” (“the Decree”).

Presidium of the FAS Russia in its Clarification dated 21.02.2018 No. 13 “On trade secrets information in the process of investigation of the case on violation of antimonopoly legislation, verification for abidance of antimonopoly legislation, state control for economic concentration” (“Clarification”) notes that such information for which information owner doesn’t establish commercial secrecy regime according to Commercial secret law, isn’t protected by law.